Usefulness of suplatast tosilate, a Th2 cytokine inhibitor based on the Thl/Th2 ratio for allergic disease in children: a retrospective study

• DOI: 10.1055/s-0031-1296221
• Publication Date: 2011-11-27T19:03:53Z
• Authors: Shigemi Yoshihara; Hironobu Fukuda; Osamu Arisaka
• Keywords: Dominance (genetics)

Children with an atopic predisposition are presumed to have persistent Th2 dominance and thus develop allergic diseases.A total of 45 children who fell dermatitis and/or intermittent asthma or mild between 2002 2007 were enrolled retrospectively analyzed. Twenty-four administered oral treatment the immunopharmacological drug suplatast tosilate (CAS 94055-76-2) at a dose 3 mg/kg twice daily. Twenty-one control group not but treated other drugs. Blood was collected before after administering drugs, Th1 cells, Th1/Th2 ratio, IgE levels, eosinophil count measured.In group, cells increased 7.9 (1.2-19.8) % from 5.5 (1.1-13.5) (Wilcoxon P < 0.05), while showed decrease 1.3 (0.5-6.5) 1.6 (0.4-2.9) %, differences significant. The ratio significantly 4.1 (0.9-7.4) 5.6 (1.3-15.5) (shifting dominance) in it shifted (increased 4.5 (2.2-12.2) 5.7 (1.6-11.8)) did show significant difference.The administration tosilate, shifting dominance. Therefore improves may inhibit subsequent progression allergy over long term.